Indivior Files New Lawsuits for Alleged Patent Infringement
September 15 2017 - 3:46AM
Dow Jones News
By Adria Calatayud
Indivior PLC (INDV.LN) said Friday that its U.S. subsidiary,
Indivior Inc., has filed lawsuits against six competitors for
alleged patent infringement after having recently lost another U.S.
patent litigation for the same product.
The U.K.-based pharmaceutical company said the lawsuits were
filed against Dr. Reddy's Laboratories Ltd. (RDY), Actavis, Par,
Alvogen Korea Co. Ltd. (002250.SE), Teva Pharmaceutical Industries
Ltd. (TEVA) and Mylan N.V. (MYL) over their respective proposed
generic versions of Suboxone oral film.
Suboxone is a buprenorphine-based treatment for opioid
dependence.
The lawsuits relate to a U.S. patent covering Suboxone issued on
June 27 and listed in the U.S. Food and Drug Administation's Orange
Book, Indivior added.
Indivior was recently involved in an another infringement suit
related to other patents covering Suboxone.
Earlier in September, Indivior said a U.S. court found that
treatments developed by Dr. Reddy's, Watson Pharmaceuticals Inc,
Endo International PLC's (ENDP) and Par hadn't infringed its
patents.
It said Friday it would appeal the decision in the suit against
Dr. Reddy's.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
September 15, 2017 03:31 ET (07:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024